Invivyd Inc. (IVVD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Invivyd Inc. (IVVD) has a cash flow conversion efficiency ratio of -0.064x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.46 Million) by net assets ($241.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Invivyd Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Invivyd Inc. carry for a breakdown of total debt and financial obligations.
Invivyd Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invivyd Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Okea ASA
OL:OKEA
|
5.688x |
|
Grand Pacific Petrochemical Corp
TW:1312
|
-0.035x |
|
China Resources Medical Holdings Company Limited
F:1PH
|
0.035x |
|
Corem Property Group AB (publ)
ST:CORE-B
|
0.015x |
|
Grieg Seafood ASA
OL:GSF
|
-0.063x |
|
Seah Holdings
KO:058650
|
-0.012x |
|
Yarward Electronics Shandong Co. Ltd. A
SHE:301337
|
N/A |
|
TWC Enterprises Ltd
TO:TWC
|
0.009x |
Annual Cash Flow Conversion Efficiency for Invivyd Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Invivyd Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Invivyd Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $241.54 Million | $-58.13 Million | -0.241x | +90.47% |
| 2024-12-31 | $67.54 Million | $-170.49 Million | -2.524x | -158.71% |
| 2023-12-31 | $177.47 Million | $-173.16 Million | -0.976x | -57.89% |
| 2022-12-31 | $355.97 Million | $-219.99 Million | -0.618x | -86.67% |
| 2021-12-31 | $558.02 Million | $-184.74 Million | -0.331x | -248.25% |
| 2020-12-31 | $-65.25 Million | $-14.57 Million | 0.223x | -- |
About Invivyd Inc.
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which i… Read more